• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down 3%; ISM Manufacturing PMI Falls In April

    5/1/24 12:17:04 PM ET
    $CETX
    $CTMX
    $CVRX
    $LEG
    Electrical Products
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CETX alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Wednesday.

    The Dow traded up 0.33% to 37,941.76 while the NASDAQ fell 0.35% to 15,603.45. The S&P 500 also fell, dropping, 0.25% to 5,023.16.

    Check This Out: This Analyst With 86% Accuracy Rate Sees More Than 24% Upside In Lattice Semiconductor – Here Are 5 Stock Picks For April From Wall Street’s Most Accurate Analysts

    Leading and Lagging Sectors

    Communication services shares rose by 1.1% on Wednesday.

    In trading on Wednesday, energy shares fell by 1.3%.

    Top Headline

    The ISM manufacturing PMI declined to 49.2 in April from 50.3 a month ago.

    Equities Trading UP
                           

    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares shot up 168% to $4.37. CytomX Therapeutics will report first quarter 2024 results and issue an initial CX-904 Phase 1a clinical data update on May 8.
    • Shares of TransMedics Group, Inc. (NASDAQ:TMDX) got a boost, surging 26% to $118.99 after the company raised its 2024 guidance.
    • Rocky Brands, Inc. (NASDAQ:RCKY) shares were also up, gaining 24% to $31.87 after the company reported better-than-expected quarterly financial results.

    Equities Trading DOWN

    • Cemtrex, Inc. (NASDAQ:CETX) shares dropped 74% to $0.3010 after the company announced pricing of a $10 million upsized underwritten public offering.
    • Shares of CVRx, Inc. (NASDAQ:CVRX) were down 42% to $8.95 after the company reported worse-than-expected first-quarter financial results. JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and lowered the price target from $36 to $13.
    • Leggett & Platt, Incorporated (NYSE:LEG) was down, falling 30% to $12.57 after the company reported worse-than-expected first-quarter financial results. The company also reduced its dividend.

    Also Check This Out: Exxon Mobil, Kimberly-Clark And 2 Other Stocks Insiders Are Selling

    Commodities

    In commodity news, oil traded down 3.2% to $79.35 while gold traded up 0.3% at $2,310.70.

    Silver traded up 0.1% to $26.67 on Wednesday, while copper fell 0.5% to $4.5405.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 slipped 0.14%, while London's FTSE 100 fell 0.34%.

    The S&P Global UK manufacturing PMI was revised higher to 49.1 in April from a preliminary reading of 48.7, while Nationwide House Price Index increased 0.6% year-over-year in April.

    Asia Pacific Markets

    Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 0.34%.

    Japan's au Jibun Bank manufacturing PMI was revised lower to 49.6 in April compared to preliminary reading of 49.9.

    Economics

    • U.S. mortgage applications declined by 2.3% from the prior week in the period ending April 26.
    • U.S. private employers added 192,000 new jobs during the month of April, compared to a revised 208,000 in March, topping market estimates of a 175,000 gain.
    • The S&P Global manufacturing PMI declined to 50 in April versus 51.9 a month ago.
    • U.S. construction spending declined by 0.2% from the prior month in March.
    • The number of job openings fell by 325,000 from the prior month to 8.488 million in March.
    • The ISM manufacturing PMI declined to 49.2 in April from 50.3 a month ago.
    • U.S. crude oil inventories rose by 7.265 million barrels in the week ending April 26, compared to a 6.368 million barrel fall in the prior week.

    Now Read This: Amazon To Rally Over 37%? Here Are 10 Top Analyst Forecasts For Wednesday

    Get the next $CETX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CETX
    $CTMX
    $CVRX
    $LEG

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    TransMedics Group Inc.
    $TMDX
    10/23/2025$148.00Hold → Buy
    Needham
    TransMedics Group Inc.
    $TMDX
    10/13/2025$145.00Buy
    Jefferies
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    CytomX Therapeutics Inc.
    $CTMX
    9/17/2025$3.50Overweight
    Barclays
    TransMedics Group Inc.
    $TMDX
    9/16/2025$155.00Outperform
    Evercore ISI
    TransMedics Group Inc.
    $TMDX
    9/4/2025$115.00Hold
    Stifel
    Rocky Brands Inc.
    $RCKY
    8/26/2025$40.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $CETX
    $CTMX
    $CVRX
    $LEG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransMedics Group upgraded by Needham with a new price target

    Needham upgraded TransMedics Group from Hold to Buy and set a new price target of $148.00

    10/23/25 7:00:10 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on TransMedics Group with a new price target

    Jefferies initiated coverage of TransMedics Group with a rating of Buy and set a new price target of $145.00

    10/13/25 8:59:30 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    President & CEO Hassanein Waleed H bought $1,000,350 worth of shares (8,775 units at $114.00) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    11/18/25 4:30:07 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Smith Dwight Eric bought $8,694 worth of shares (300 units at $28.98), increasing direct ownership by 2% to 14,207 units (SEC Form 4)

    4 - ROCKY BRANDS, INC. (0000895456) (Issuer)

    11/7/25 4:20:17 PM ET
    $RCKY
    Shoe Manufacturing
    Consumer Discretionary

    $CETX
    $CTMX
    $CVRX
    $LEG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Cecere Giovanni

    3 - TransMedics Group, Inc. (0001756262) (Issuer)

    2/12/26 4:15:03 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Pres. - Spec. and FF&T Smith Robert S Jr was granted 243 shares, increasing direct ownership by 0.23% to 107,856 units (SEC Form 4)

    4 - LEGGETT & PLATT INC (0000058492) (Issuer)

    2/9/26 2:50:21 PM ET
    $LEG
    Home Furnishings
    Consumer Discretionary

    $CETX
    $CTMX
    $CVRX
    $LEG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cemtrex Reports Fiscal Year 2026 First Quarter Financial Results

    Hauppauge, NY, Feb. 17, 2026 (GLOBE NEWSWIRE) -- – Cemtrex, Inc. (NASDAQ:CETX, CETXP)) today reported results for the 2026 first fiscal quarter ended December 31, 2025. Key Highlights for First Fiscal Quarter 2026 Revenues for Q1 '26 increased 17% to $16.1 million, compared to revenue in the prior year of $13.7 million.Industrial segment revenue increased 28% to $10.6 million, compared to revenue in the prior year of $8.3 million.Security segment revenue increased 1% to $5.5 million, compared to revenue in the prior year of $5.4 million.Cash and cash equivalents increased 312% to $20.5 million, compared to the prior year of $5 million. Management Commentary Cemtrex Chairman and CEO, S

    2/17/26 4:15:00 PM ET
    $CETX
    Electrical Products
    Technology

    Rocky Brands, Inc. to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026

    Rocky Brands, Inc. (NASDAQ:RCKY) today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2025, after the market close on Tuesday, February 24, 2026. Management will host a conference call that afternoon (February 24, 2026) at 4:30 p.m. ET to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial (877) 704-4453 (domestic) or (201) 389-0920 (international). The conference call will also be available to interested parties through a live webcast at www.rockybrands.com. Please visit the website and select the "Investor Relations" link at least 15 minutes prior to the start

    2/17/26 4:06:00 PM ET
    $RCKY
    Shoe Manufacturing
    Consumer Discretionary

    TransMedics to Present at Upcoming March Investor Conferences

    ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026, at 1:50 p.m. EST and virtually at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Monday, March 16, 2026, at 10:00 a.m. EST.

    2/17/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/17/26 6:23:44 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cemtrex Inc.

    10-Q - CEMTREX INC (0001435064) (Filer)

    2/17/26 4:16:13 PM ET
    $CETX
    Electrical Products
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/17/26 4:15:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

    ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

    12/2/24 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Financials

    Live finance-specific insights

    View All

    Rocky Brands, Inc. to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026

    Rocky Brands, Inc. (NASDAQ:RCKY) today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2025, after the market close on Tuesday, February 24, 2026. Management will host a conference call that afternoon (February 24, 2026) at 4:30 p.m. ET to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial (877) 704-4453 (domestic) or (201) 389-0920 (international). The conference call will also be available to interested parties through a live webcast at www.rockybrands.com. Please visit the website and select the "Investor Relations" link at least 15 minutes prior to the start

    2/17/26 4:06:00 PM ET
    $RCKY
    Shoe Manufacturing
    Consumer Discretionary

    Rocky Brands Declares Quarterly Cash Dividend

    Rocky Brands, Inc. (NASDAQ:RCKY) today announced that its board of directors has declared a quarterly cash dividend of $0.155 per share of outstanding common stock, which will be paid on March 16, 2026, to all shareholders of record as of the close of business on March 2, 2026. The declaration and payment of future dividends and the establishment of future record dates and payment dates are subject to the quarterly determination of the board of directors. About Rocky Brands, Inc. Rocky Brands, Inc. is a leading designer, manufacturer and marketer of premium quality footwear and apparel marketed under a portfolio of well recognized brand names. Brands in the portfolio include Rocky®, G

    2/17/26 4:05:00 PM ET
    $RCKY
    Shoe Manufacturing
    Consumer Discretionary

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CETX
    $CTMX
    $CVRX
    $LEG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cemtrex Inc.

    SC 13G - CEMTREX INC (0001435064) (Subject)

    11/14/24 5:51:51 PM ET
    $CETX
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care